Huber Capital Management LLC Has $4.24 Million Stock Position in Pfizer Inc. (NYSE:PFE)

Huber Capital Management LLC lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 354.2% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 151,446 shares of the biopharmaceutical company’s stock after purchasing an additional 118,100 shares during the period. Huber Capital Management LLC’s holdings in Pfizer were worth $4,237,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of the business. Cantor Fitzgerald Investment Advisors L.P. acquired a new stake in shares of Pfizer in the fourth quarter valued at about $16,166,000. LGT Group Foundation increased its position in Pfizer by 2.5% during the 2nd quarter. LGT Group Foundation now owns 742,875 shares of the biopharmaceutical company’s stock valued at $20,786,000 after purchasing an additional 18,274 shares during the period. ORG Partners LLC lifted its position in shares of Pfizer by 1,729.9% in the 2nd quarter. ORG Partners LLC now owns 47,028 shares of the biopharmaceutical company’s stock worth $1,327,000 after purchasing an additional 44,458 shares during the period. Kempner Capital Management Inc. bought a new stake in shares of Pfizer in the 1st quarter valued at $2,439,000. Finally, Leo Wealth LLC acquired a new stake in shares of Pfizer during the fourth quarter worth $2,171,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

PFE stock opened at $29.42 on Friday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. The business has a 50-day simple moving average of $29.36 and a two-hundred day simple moving average of $28.22. The company has a market capitalization of $166.71 billion, a P/E ratio of -490.25, a price-to-earnings-growth ratio of 1.05 and a beta of 0.68. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $34.11.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The company had revenue of $13.28 billion for the quarter, compared to analysts’ expectations of $12.96 billion. During the same quarter in the previous year, the firm earned $0.67 earnings per share. Pfizer’s quarterly revenue was up 2.1% on a year-over-year basis. Research analysts expect that Pfizer Inc. will post 2.66 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 3rd. Investors of record on Friday, July 26th were issued a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 5.71%. The ex-dividend date was Friday, July 26th. Pfizer’s dividend payout ratio (DPR) is presently -2,799.53%.

Wall Street Analyst Weigh In

PFE has been the topic of a number of research analyst reports. UBS Group upped their price target on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research report on Wednesday, July 31st. StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Wells Fargo & Company increased their price target on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Barclays lifted their price objective on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Finally, Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and raised their price target for the stock from $28.00 to $34.00 in a report on Wednesday, August 7th. Eight equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $34.54.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.